Patents by Inventor Bhaumik A. Pandya

Bhaumik A. Pandya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND USES THEREOF
    Publication number: 20240124435
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: September 27, 2023
    Publication date: April 18, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
  • Compounds and uses thereof
    Patent number: 11873298
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: January 16, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20230355629
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: December 9, 2022
    Publication date: November 9, 2023
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION
    Publication number: 20230136787
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting VEGF-A, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of VEGF-A.
    Type: Application
    Filed: February 9, 2021
    Publication date: May 4, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAMES D. MCININCH, MARK KEATING, MARK K. SCHLEGEL, ADAM CASTORENO, VASANT R. JADHAV, CHARALAMBOS KAITTANIS, ELENA CASTELLANOS-RIZALDOS, BHAUMIK A. PANDYA
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230116101
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: November 13, 2020
    Publication date: April 13, 2023
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230078764
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: March 20, 2020
    Publication date: March 16, 2023
    Inventors: Bertrand LE BOURDONNEC, Matthew LUCAS, Kerem OZBOYA, Bhaumik PANDYA, Daniel TARDIFF, Parcharee TIVITMAHAISOON, Iwona WRONA
  • COMPOUNDS AND USES THEREOF
    Publication number: 20220298168
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: September 22, 2020
    Publication date: September 22, 2022
    Inventors: Bertrand LE BOURDONNEC, Matthew LUCAS, Kerem OZBOYA, Bhaumik PANDYA, Daniel TARDIFF, Parcharee TIVITMAHAISOON, Iwona WRONA
  • COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS
    Publication number: 20220110920
    Abstract: The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: Rebecca ARON, Bhaumik PANDYA, Daniel TARDIFF, Jeff PIOTROWSKI, Matthew LUCAS, Bertrand LE BOURDONNEC, Kenneth RHODES, Robert SCANNEVIN
  • Compositions and methods for the treatment and prevention of neurological disorders
    Patent number: 11241417
    Abstract: The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: February 8, 2022
    Assignee: Yumanity Therapeutics, Inc.
    Inventors: Rebecca Aron, Bhaumik Pandya, Daniel Tardiff, Jeff Piotrowski, Matthew Lucas, Bertrand Le Bourdonnec, Kenneth Rhodes, Robert Scannevin
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20210330674
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: December 10, 2020
    Publication date: October 28, 2021
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • COMPOUNDS AND USES THEREOF
    Publication number: 20210139471
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 13, 2021
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC
  • Compounds and uses thereof
    Patent number: 10919885
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: February 16, 2021
    Assignee: Yumanity Therapeutics, Inc.
    Inventors: Iwona Wrona, Parcharee Tivitmahaisoon, Daniel Tardiff, Bhaumik Pandya, Kerem Ozboya, Matthew Lucas, Bertrand Le Bourdonnec
  • COMPOUNDS AND USES THEREOF
    Publication number: 20200262828
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 20, 2020
    Inventors: Matthew LUCAS, Bertrand LE BOURDONNEC, Iwona WRONA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Kerem OZBOYA, Benjamin VINCENT, Daniel TARDIFF, Jeff PIOTROWSKI, Eric SOLIS, Robert SCANNEVIN, Chee-Yeun CHUNG, Rebecca ARON, Kenneth RHODES
  • COMPOUNDS AND USES THEREOF
    Publication number: 20200010462
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: October 24, 2017
    Publication date: January 9, 2020
    Inventors: Matthew LUCAS, Bertrand LE BOURDONNEC, Iwona WRONA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Kerem OZBOYA, Benjamin VINCENT, Daniel TARDIFF, Jeff PIOTROWSKI, Eric SOLIS, Robert SCANNEVIN, Chee-Yeun CHUNG, Rebecca ARON, Kenneth Rhodes
  • COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS
    Publication number: 20190388397
    Abstract: The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression.
    Type: Application
    Filed: June 21, 2019
    Publication date: December 26, 2019
    Inventors: Rebecca ARON, Bhaumik PANDYA, Daniel TARDIFF, Jeff PIOTROWSKI, Matthew LUCAS, Bertrand LE BOURDONNEC, Kenneth RHODES, Robert SCANNEVIN
  • COMPOUNDS AND USES THEREOF
    Publication number: 20190330198
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: April 24, 2019
    Publication date: October 31, 2019
    Inventors: Iwona WRONA, Parcharee TIVITMAHAISOON, Daniel TARDIFF, Bhaumik PANDYA, Kerem OZBOYA, Matthew LUCAS, Bertrand Le BOURDONNEC
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20190308976
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: March 11, 2019
    Publication date: October 10, 2019
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20170239254
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: March 9, 2017
    Publication date: August 24, 2017
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • Derivatives of pyrazole-substituted amino-heteroaryl compounds
    Patent number: 9707218
    Abstract: This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: July 18, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Bhaumik A. Pandya, Craig E. Masse, Ian Robert Silverman, Roger D. Tung
  • Substituted xanthine derivatives
    Patent number: 9328113
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentifylline and related compounds are beneficial.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: May 3, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Roger D. Tung, Bhaumik Pandya, Scott L. Harbeson